This review included two Cochrane reviews, 14 meta-analyses and 15 trials. Ketamine was studied versus placebo, versus other comparators and as an anesthetic adjuvant before electroconvulsive therapy. In 14 publications, ketamine provided a rapid antidepressant effect with a maximum efficacy reached at 24 hrs. Its effect lasted for 1-2 weeks after infusion, but a longer-term effect is little reported. Ketamine does not seem to improve depressive symptoms at the end of electroconvulsive sessions. Safety and tolerability profiles with ketamine at low single dose are generally good in depressed patients.
Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review
Zach Walsh, Ozden Merve Mollaahmetoglu, Joseph Rootman, Shannon Golsof, Johanna Keeler, Beth Marsh, David J. Nutt and Celia J. A. Morgan